Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
ORIGINAL ARTICLE
Year : 2014  |  Volume : 10  |  Issue : 3  |  Page : 681-685

Serum ferritin is elevated in advanced non-small cell lung cancer patients and is associated with efficacy of platinum-based chemotherapy


1 Department of Oncology, The Third Affiliated Hospital of Soochow University, Changzhou 213003, Jiangsu Province, China
2 Department of Tumor Biological Treatment, The Third Affiliated Hospital of Soochow University, Changzhou 213003, Jiangsu Province, China

Correspondence Address:
Mei Ji
Department of Tumor Biological Treatment, The Third Affiliated Hospital of Soochow University, 185 Juqian Street, Changzhou 213003, Jiangsu Province
China
Login to access the Email id

Source of Support: This work was funded by grants from the Major Bidding Project Changzhou Health Bureau (ZD200810) provided by Dr. Mei Ji, Conflict of Interest: None


DOI: 10.4103/0973-1482.139156

Rights and Permissions

Aim: The aim of this study was to determine the expression levels of serum ferritin (SF) and investigate the correlation between SF expression levels and clinical characteristics as well as the efficacy to platinum-based chemotherapy for advanced non-small cell lung cancer (NSCLC) patients. Materials and Methods: Electrochemiluminescence method was used to determine the expression levels of SF in the peripheral blood of 46 advanced NSCLC patients and 63 healthy subjects. Results: The expression levels of SF in healthy subjects were significantly lower than those in patients with advanced NSCLC patients (t = −3.279,P = 0.001). There was a statistically significant difference between SF expression levels and distant metastasis, regional lymph node metastasis, respectively (P < 0.05). However, there was no correlation between SF expression levels and sex, age, eastern cooperative oncology group performance status, smoking history, pathological type, tumor location and tumor-node-metastasis stage (All P > 0.05). The overall response rate to platinum-based chemotherapy was 57.1% (12/21) in normal SF expression levels group, which was significantly higher than that was 28% (7/25) in high SF expression levels group (χ2 = 3.998,P = 0.046). Conclusions: SF may be a valuable blood marker for predicting the tumor progression and the efficacy of platinum-based therapies for advanced NSCLC patients.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed2005    
    Printed63    
    Emailed0    
    PDF Downloaded87    
    Comments [Add]    

Recommend this journal